Shares of Boston Scientific Corp. (NYSE:BSX) reached a new 52-week high during trading on Tuesday . The stock traded as high as $23.99 and last traded at $23.69, with a volume of 4,840,501 shares traded. The stock had previously closed at $23.77.

Several research firms recently commented on BSX. TheStreet upgraded shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating in a report on Wednesday, April 27th. BTIG Research cut shares of Boston Scientific Corp. from a “buy” rating to a “neutral” rating and set a $24.20 price target for the company. in a report on Monday, May 23rd. Benchmark Co. restated a “buy” rating and set a $22.00 price target (up from $20.00) on shares of Boston Scientific Corp. in a report on Wednesday, April 27th. Bank of America Corp. restated a “buy” rating and set a $23.00 price target on shares of Boston Scientific Corp. in a report on Friday, March 25th. Finally, Zacks Investment Research upgraded shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a report on Thursday, May 12th. Four research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $23.49.

The firm’s market cap is $32.06 billion. The firm has a 50 day moving average price of $22.96 and a 200-day moving average price of $19.85.

Boston Scientific Corp. (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 27th. The company reported $0.28 EPS for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.04. The firm had revenue of $1.96 billion for the quarter, compared to analyst estimates of $1.91 billion. During the same period in the previous year, the business posted $0.21 earnings per share. The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. Analysts forecast that Boston Scientific Corp. will post $1.09 EPS for the current fiscal year.

In other news, EVP Timothy A. Pratt sold 24,229 shares of Boston Scientific Corp. stock in a transaction dated Wednesday, June 1st. The stock was sold at an average price of $22.66, for a total transaction of $549,029.14. Following the sale, the executive vice president now directly owns 301,724 shares of the company’s stock, valued at $6,837,065.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jeffrey B. Mirviss sold 24,659 shares of Boston Scientific Corp. stock in a transaction dated Friday, May 6th. The shares were sold at an average price of $21.94, for a total value of $541,018.46. Following the sale, the senior vice president now directly owns 71,975 shares in the company, valued at $1,579,131.50. The disclosure for this sale can be found here.

Several hedge funds have recently made changes to their positions in the stock. Tredje AP fonden raised its stake in shares of Boston Scientific Corp. by 1.3% in the fourth quarter. Tredje AP fonden now owns 86,021 shares of the company’s stock worth $1,586,000 after buying an additional 1,138 shares during the last quarter. Comerica Bank raised its position in Boston Scientific Corp. by 0.4% in the fourth quarter. Comerica Bank now owns 333,885 shares of the company’s stock worth $5,820,000 after buying an additional 1,206 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Boston Scientific Corp. by 1.8% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 87,889 shares of the company’s stock worth $1,621,000 after buying an additional 1,540 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Boston Scientific Corp. by 7.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 57,502 shares of the company’s stock worth $1,061,000 after buying an additional 3,945 shares in the last quarter. Finally, Advantus Capital Management Inc raised its position in Boston Scientific Corp. by 3.7% in the fourth quarter. Advantus Capital Management Inc now owns 130,685 shares of the company’s stock worth $2,410,000 after buying an additional 4,604 shares in the last quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.